Astellas Pharma Patent-Cliff Exposure & CMS Drug Spending Portfolio

Astellas Pharma (Northbrook, IL): 17 reconciled FDA prescription therapies (96.0% 2025 to 2030 cliff risk), $6.40B 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterNorthbrook, IL
Reconciled FDA Portfolio Therapies17
2025 to 2030 Patent-Cliff Revenue Exposure96.0%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$6.40B
2024 Medicare Part D Spend$5.99B
2024 Medicaid Spend$406.6M
California HCAI SB 17 Filings11 WAC filings (max 25.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.